This medication is used in situations involving certain distressing symptoms across therapeutic domains. It is commonly used across conditions presenting with acute episodes and symptoms that create noticeable physiological strain.

Symptom Management and Functional Support

This product is applied across domains where short-term symptom management is appropriate. It contributes to easing the overall symptom load and helps address symptoms related to physical discomfort by supporting the management of associated tissue changes and swelling. The therapeutic benefit supports patients during episodes of heightened discomfort by helping to ease the associated symptom clusters and assists with maintaining functional stability.

It is relevant for easing symptoms in conditions characterized by periods of heightened symptoms, including chronic pelvic inflammatory disease (PID), inflammation of the tubes and ovaries (salpingo-oophoritis), acute and chronic hemorrhoidal disease, and in the early postoperative period to manage tissue changes following abdominal or pelvic surgery.

“This supportive management is often applied in clinical settings that involve acute or unstable symptom patterns where temporary symptomatic assistance is needed.”

---

Quick Fact: Support for Localized Symptoms
Primary Domain	Inflammation with significant localized symptoms
Use Context	Acute symptomatic episodes and postoperative support
Symptom Goal	Easing associated discomfort and swelling

Regulatory References

1. Streptodornase and Streptokinase - MeSH - NCBI

Who can and cannot use Distreptaza?

The official regulatory labeling for Distreptaza (Streptokinase/Streptodornase suppositories) defines specific populations and conditions that determine eligibility for use.

Populations for whom use is Contraindicated

The medicine must not be used by the following groups, as explicitly stated in contraindications sections of regulatory documents:

• Patients with documented hypersensitivity to the active substances (Streptokinase, Streptodornase) or any of the inactive ingredients.
• Patients with wounds covered with a fresh scab or who have surgical sutures in the area where the suppository is to be applied.
• Patients receiving concurrent treatment with anticoagulant drugs or other medicines containing calcium salts.
• Pregnant patients and breastfeeding patients.

Age-Related Eligibility

Age Group	Regulatory Eligibility Status
Adults and Older Adults	Eligible for use under standard guidelines. No dosage adjustment information is necessary for patients over 65 years old.
Children and Adolescents	Use is not recommended. Safety and efficacy have not been established in this population group, according to regulatory data.

Organ Function Status

Use is generally permitted for patients with impaired organ function, as Distreptaza is locally administered and not subject to systemic metabolism:

• Renal or Hepatic Impairment: No information of dosage adjustment is necessary for patients with kidney or liver function disorders.

The official regulatory documents for Distreptaza suppositories define a specific interaction profile that is constrained by the product’s local route of administration and lack of systemic metabolism. This profile focuses on mandatory co-administration restrictions rather than complex metabolic considerations.

Documented Co-administration Restrictions

The regulatory prescribing information explicitly prohibits the concurrent use of Distreptaza with certain agents:

• Anticoagulant Agents: Co-administration with anticoagulant drugs is strictly prohibited. This is classified as a pharmacodynamic interaction that results in an increased risk of local bleeding.
• Calcium Salts: The product should not be used concurrently with other medicinal products containing Calcium salts. This constitutes a mandatory co-administration avoidance rule specified in the official label.

Pharmacokinetic and Systemic Considerations

The interaction profile is characterized by an absence of documented systemic interactions. Because the active components are administered locally and are not reported to be metabolized by the liver, the regulatory label does not document interactions involving common metabolic pathways, such as CYP enzymes. Consequently, no substances are officially reported to modify the systemic exposure (e.g., clearance or plasma levels) of the active ingredients. Additionally, the official prescribing information does not list specific interactions with food, alcohol, or herbal products.

Distreptaza is a dual-enzyme preparation that utilizes two distinct mechanisms to chemically degrade pathological debris at the localized site of administration, resulting in liquefaction of the material.

The component Streptokinase acts indirectly by binding to the endogenous zymogen Plasminogen, converting it into the active serine protease, Plasmin. This localized Plasmin activity hydrolyzes the structural protein Fibrin, leading to the chemical degradation of the protein scaffolding that forms the organized structure of inflammatory masses.

The second component, Streptodornase, operates by directly catalyzing the breakdown of high-molecular-weight Extracellular DNA (eDNA), the main factor responsible for the high viscosity of purulent material. This action transforms the thick, gel-like structure into a liquid state, significantly reducing its viscosity.

The enzymes work synergistically: the degradation of the fibrin mesh exposes the debris core, while the liquefaction of the core promotes the overall degradation of the mass. This dual-targeted approach results in the full chemical degradation of the complex physical structures (fibrin and eDNA), which facilitates the localized clearance of material.

Distreptaza is a localized enzyme preparation delivered exclusively via the rectal route, ensuring the active components, 15000 IU of Streptokinase and 1250 IU of Streptodornase per unit, are concentrated at the site of administration. The administration is formalized through specific, phased courses that dictate the dosage frequency over a defined period.

The standard course of treatment is designed to last between seven and ten days and is defined by two primary labeled regimens that determine the required daily frequency. Administration can range from once daily up to three times daily in the initial phases, with the frequency systematically decreasing over the cycle duration. For intensive application, the course involves administering a suppository three times daily for the first three days, followed by a reduction to two times daily for the subsequent three days, and concludes with a final three days of once-daily use. Less intensive cycles typically begin with twice-daily use and transition to once-daily administration over the required duration.

For proper administration, the suppository must be inserted deeply into the rectum immediately after removal from its packaging. Use is also detailed according to patient population. No specific dosage adjustment is required for older adults or for patients with hepatic impairment, due to its localized action. However, its use in children and adolescents is not established and is therefore not indicated for this group. The drug's use is strictly procedural, governed by these defined administration cycles.

Research Evidence / Overview of Studies for Distreptaza

Evidence for Use in Acute Hemorrhoidal Disease

Research exploring this enzymatic preparation for conditions characterized by fluctuating or episodic manifestations, such as acute hemorrhoidal disease, was evaluated in short-term clinical trials. These studies, which include controlled trials against placebo or other local preparations, were conducted to track how symptoms change over time in adult populations experiencing acute symptoms of physical discomfort and swelling. The research examined outcomes related to physical discomfort, specifically measuring the disappearance of pain and the reduction of edema. Findings describe patterns observed in the studies, where the primary component of the preparation was evaluated in research settings against other forms of local management. Comparative evidence is lacking regarding the specific contribution of the combination product itself, as many high-quality trials focused on recombinant Streptokinase (rSK) alone. Furthermore, follow-up durations were limited, focusing mainly on short-term results.

Evidence for Use in Pelvic Inflammatory Conditions

Research exploring this preparation for conditions involving periods of heightened symptoms in the pelvic area, such as chronic pelvic inflammatory disease (PID) or abscesses, was evaluated in historical clinical studies and case series, often used in research settings alongside standard treatments like antibiotics. The studies monitored outcomes associated with local tissue changes, describing how changes in the size of pelvic masses or abscesses were observed in the research populations. Evidence quality varies across studies, and there is a lack of recent, large-scale comparative research, such as Randomized Controlled Trials, evaluating the combined suppository preparation against current therapeutic protocols for PID.

What is Still Uncertain About Distreptaza

Key uncertainties exist because many controlled trials for hemorrhoidal disease was observed in studies that only used the recombinant Streptokinase (rSK) component alone. This leaves a gap in understanding the specific findings related to the Streptodornase component within the combined product. Furthermore, comparative evidence is lacking across several indications, and the long-term effects are not fully established, with additional research being ongoing. Data for certain groups remain insufficient, as the core evidence has focused on the adult population.

Common questions about Distreptaza (FAQ)

Q: Does Distreptaza cause drowsiness or affect driving?

A: According to the official product information, Distreptaza is not listed as a medicine that causes drowsiness. Regulatory documents state that this medicine does not affect the ability to drive vehicles or operate machinery.

Q: Are there any specific foods or drinks to avoid while using Distreptaza?

A: The official prescribing information does not list any specific foods or non-alcoholic drinks that need to be avoided while using this product. The medicine's mechanism of localized action means that systemic dietary restrictions are generally not addressed in regulatory documents.

Q: Is it possible to become dependent on Distreptaza?

A: Official regulatory documentation does not list the potential for dependence or addiction as a known risk or side effect associated with the use of Distreptaza. Its mechanism is focused on local enzyme activity, and dependence is not listed in the official safety information.

Q: Is Distreptaza a steroid medicine?

A: Distreptaza is not a steroid medicine. It is classified as an enzymatic preparation, specifically known as a fibrinolytic and necrolytic agent. These classifications refer to its function in dissolving pathological materials such as fibrin and pus.

Q: Is it possible to take too much Distreptaza?

A: Regulatory product information addresses the possibility of overdose, noting that only symptomatic treatment should be administered. If a suspected overdose of the medicine occurs, official sources state that medical advice may be sought.

Q: Does Distreptaza interact with oral contraceptives?

A: The official prescribing information does not list an interaction between Distreptaza and oral contraceptives. This is consistent with its localized route of administration, and the medicine is not reported to be absorbed in ways that would affect systemic medications.

Q: Why do official documents mention Distreptaza being used with other medications?

A: Official documentation explains the use of Distreptaza alongside other treatments, such as antibiotics. The enzymatic action helps liquefy dense materials like blood clots and pus components. This process is described as facilitating the penetration of co-administered medicines to the site of inflammation or infection.

Q: Is Distreptaza used for abscesses or boils?

A: Regulatory indications for Distreptaza include supportive treatment for specific localized issues, such as perianal abscesses and fistulas that involve extensive inflammatory infiltration. The medicine is used to support the resolution of this type of deeply lodged inflammatory issue.

Q: Can I use alcohol while taking Distreptaza?

A: The official prescribing information does not list a specific interaction with alcohol. This aligns with the medicine's local route of administration and lack of documented systemic metabolism.

Q: Is it normal to feel a mild burning sensation after using Distreptaza?

A: The product information lists local pain and local swelling as possible, rare side effects at the administration site. While a mild burning sensation is not explicitly named, it falls under the category of local discomfort. Any persistent or severe local reaction is a topic to discuss with a healthcare professional.

Q: If I have a known allergy to Streptococci, can I still use Distreptaza?

A: Distreptaza is contraindicated for individuals with known hypersensitivity to the active substances, Streptokinase and Streptodornase. Regulatory information notes these enzymes are biopreparations derived from cultures of beta-hemolytic streptococci when defining the specific restriction.

Q: What is the regulatory status of Distreptaza in major countries like the US or EU?

A: Distreptaza holds a marketing authorization in countries within the European Union (EU), where its use is guided by EMA documentation. Authoritative sources indicate that it is not widely available or approved in the United States.

Q: What are the main differences between Distreptaza and other enzyme-based drugs?

A: Distreptaza is a dual-enzyme preparation containing two active substances: Streptokinase and Streptodornase. Official pharmacological documents explain that this combination allows it to break down both the structural protein (fibrin matrix) and the thick components of pus (eDNA). This synergistic, dual-targeted action is a key feature of its pharmacological profile.

Q: Is Distreptaza available over the counter?

A: Distreptaza is designated as a prescription-only medicine in the regulatory contexts where it is approved. It is not available for purchase over the counter.

How to Store and Dispose of Distreptaza

The storage and disposal requirements for Distreptaza suppositories are based on official government labeling to maintain the stability of this enzyme biopreparation.

Mandatory Storage Conditions

The medicine must be stored in a refrigerator within a temperature range of 2 C to 8 C. It is prohibited to freeze the product, as this can compromise the suppository and the active enzymes. To ensure the integrity of the contents, the product must be kept in its original outer carton and must not be used past the expiration date listed on the package.

Storage Restriction	Requirement
Temperature	Store between 2 C and 8 C
Prohibited	Do not freeze
Access	Keep out of the sight and reach of children

Official Disposal Rules

Expired or unused Distreptaza must not be thrown away via household waste or wastewater. Instead, the product must be returned to a pharmacist or a designated local collection point to ensure appropriate disposal according to local environmental regulations.